GlassScriptPhysician profile
Nabil M Ahmad
NPI 1235131319
$88,331.63
in general payments reported to CMS, 2019-2025
27 companies · $9,995 in 2025
The $9,995 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,070 · 2020: $4,907 · 2021: $48K · 2022: $5,940 · 2023: $5,967 · 2024: $4,991 · 2025: $9,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $14K · Debt Forgiveness: $4,875 · Travel and Lodging: $852 · Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $14,400.00 |
| Debt Forgiveness | $4,875.43 |
| Travel and Lodging | $852.40 |
| Food and Beverage | $825.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $79,947.10 | 2019-2025 | Venacure 1470 Pro |
| Merit Medical Systems INC | $4,875.43 | 2025 | |
| Philips North America LLC | $887.77 | 2022-2023 | (9520) Igt Devices Undivided |
| Cardiovascular Systems INC. | $622.76 | 2022 | |
| Abbott Laboratories | $507.63 | 2019-2023 | Assurity |
| Amgen INC. | $275.64 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $202.03 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Pfizer INC. | $139.59 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $102.17 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $96.40 | 2019-2023 | |
| Scpharmaceuticals INC. | $88.17 | 2024-2025 | |
| Biotronik INC. | $80.05 | 2019 | |
| Shockwave Medical, INC | $76.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.67 | 2019-2025 | Jardiance |
| Medtronic, INC. | $61.90 | 2023-2024 | Cobalt Dr Mri Surescan, Mycarelink |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.53 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $38.95 | 2025 | Farapulse |
| Janssen Pharmaceuticals, INC | $30.90 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $29.22 | 2023 | Inpefa |
| Veryan Medical Incorporated | $28.73 | 2022 | |
| Medtronic Vascular, INC. | $22.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.57 | 2019 | |
| Braemar Manufacturing, LLC | $19.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.07 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.53 | 2019 | |
| Amarin Pharma, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.